NEW YORK (GenomeWeb) – Exosome Diagnostics said today that it has entered into an agreement with Merck KGaA, in which it will help further the company's drug development efforts.

The collaboration will cover therapeutic development in oncology and other disease areas, and will use Exosome's proprietary technology platforms for nucleic acid and protein detection from circulating exosomes, the firm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.